[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634194":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":22,"centralContacts":29,"locations":37,"responsibleParty":52,"collaborators":22,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":22,"enrollmentInfo":65,"targetDuration":22,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":22,"overallStatus":40,"whyStopped":22,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Medical University of Vienna","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Diabetes mellitus GLP1-RA","EXPERIMENTAL","Measurements of the Ocular Blood Flow and Retinal Oxygen Extraction are performed.",[13,14,15],"Device: • Laser Speckle Flowgraphy (LSFG)","Device: • Optical Coherence Tomography (OCT)","Device: • Optical Coherence Tomography Angiography (OCT-A)",[17,23,26],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"DEVICE","• Laser Speckle Flowgraphy (LSFG)","Laser Speckle Flowgraphy (LSFG)",[9],null,{"type":18,"name":24,"description":24,"armGroupLabels":25,"otherNames":22},"• Optical Coherence Tomography (OCT)",[9],{"type":18,"name":27,"description":27,"armGroupLabels":28,"otherNames":22},"• Optical Coherence Tomography Angiography (OCT-A)",[9],[30,35],{"name":31,"role":32,"phone":33,"phoneExt":22,"email":34},"Doreen Schmidl, Prof. Priv. Doz. MD.; PhD","CONTACT","+431404002981","doreen.schmidl@meduniwien.ac.at",{"name":36,"role":32,"phone":33,"phoneExt":22,"email":22},"Doreen Schmidl, Prof. Priv. Doz. MD, PhD",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":22},"Medical University Vienna","RECRUITING","Vienna","State of Vienna","1090","Austria","AT",{"type":47,"coordinates":48},"Point",[49,50],16.37208,48.20849,{"lat":50,"lon":49},{"type":53,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"PRINCIPAL_INVESTIGATOR","Doreen Schmidl","Assoc. Prof. Priv. Doz. Dr., PhD","100634194","measurement-of-ocular-blood-flow-and-retinal-oxygen-extraction-in-diabetic-patients-100634194",false,"NCT07536516","Measurement of Ocular Blood Flow and Retinal Oxygen Extraction in Diabetic Patients","DM OPF ROXY","Inclusion Criteria:\n\n* Men and women aged ≥ 18 years\n* Signed informed consent\n* Previously diagnosed diabetes mellitus\n* Normal ophthalmic findings except diabetic retinopathy, unless the investigator considers an abnormality to be clinically irrelevant\n* Planned initiation of therapy with GLP-1 receptor agonist (Semaglutide, Ozempic®; Liraglutide, Victoza®) or GIP\u002FGLP-1 receptor agonist (Tirzepatide, Mounjaro®) by a diabetes specialist\n\nExclusion Criteria:\n\n* Participation in a clinical trial in the 3 weeks preceding the screening visit\n* Symptoms of a clinically relevant illness in the 3 weeks before the first study day\n* Presence or history of a severe medical condition, except diabetes, as judged by the clinical investigator\n* Abuse of alcoholic beverages\n* Blood donation during the previous three weeks\n* Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator\n* Previous laser photocoagulation treatment in the study eye\n* Best corrected visual acuity \\\u003C 0.4 Snellen\n* Women of childbearing potential (neither menopausal, nor hysterectomized, nor sterilized) not using effective contraception\n* Pregnancy, planned pregnancy or lactation","ALL","18 Years",{"count":66,"type":67},20,"ESTIMATED","INTERVENTIONAL",[70],"NA","The prevalence of diabetes is increasing, with type 2 diabetes mellitus comprising over 90% of cases. Diabetes mellitus complications, including diabetic retinopathy (DR), impose significant health burdens. GLP-1 receptor agonists (GLP-1RAs) and dual GIP\u002FGLP-1 receptor agonists show promise in improving cardiovascular and kidney outcomes, but their effects on retinal microvasculature and neuroprotection remain unclear. This study investigates the impact of GLP-1RAs (semaglutide, liraglutide) and GIP\u002FGLP-1-dual agonists (tirzepatide) on ocular blood flow and retinal function in DM patients.",[73],"Diabetes Mellitus","2026-04-10",{"date":76,"type":77},"2026-04-17","ACTUAL",{"date":79,"type":77},"2025-11-28",{"date":81,"type":67},"2026-06-01",{"name":5,"class":6},1]